A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Arslan S, Cutler C, Alousi A, Hamadani M, Abhyankar SH, Pusic I, Ross M, Schiller G, Dash A, Liu W, Yu Y, Lekkerkerker A, Wong C, Peck MC. A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2026 May 31:S2666-6367(26)00443-4. doi: 10.1016/j.jtct.2026.05.042. Epub ahead of print. PMID: 42225184.


Related Posts